H.R. 5343 119th Congress
Ensuring Patient Access to Critical Breakthrough Products Act
- Health
- Sponsor: Rep. Moore, Blake D. [R-UT-1]
- Congress.gov ↗
Latest action, Sep 17, 2025: Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 37 - 3.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
68 cosponsors
Sponsored by Rep. Moore, Blake D. [R-UT-1] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
33 D · 35 R
Referred to: House: Energy and Commerce Committee; House: Ways and Means Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
5 reports
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED)
THE NICKLES GROUP, LLC
5 reports
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED)
CROSSROADS STRATEGIES, LLC
5 reports
5 reports
5 reports
EDWARDS LIFESCIENCES LLC
AVENUE SOLUTIONS
5 reports
5 reports
LIFE SCIENCES PENNSYLVANIA
5 reports
MEDICAL DEVICE MANUFACTURERS ASSOCIATION
THE MCMANUS GROUP
5 reports
5 reports
5 reports
5 reports
ROCHE DIAGNOSTICS
THE MCMANUS GROUP
5 reports
All 25 of 34 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ADVANCED MEDICAL TECHNOLOGY ASSN | 5 | $5.0M | Q4 2025 | Q3 2026 | yes | |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | THE NICKLES GROUP, LLC | 5 | $300K | Q4 2025 | Q3 2026 | yes |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | CROSSROADS STRATEGIES, LLC | 5 | $250K | Q4 2025 | Q3 2026 | yes |
| BOSTON SCIENTIFIC CORPORATION | 5 | $3.1M | Q4 2025 | Q3 2026 | yes | |
| EDWARDS LIFESCIENCES LLC | 5 | $1.6M | Q4 2025 | Q3 2026 | yes | |
| EDWARDS LIFESCIENCES LLC | AVENUE SOLUTIONS | 5 | $0 | Q4 2025 | Q3 2026 | yes |
| F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 5 | $520K | Q4 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 5 | $11.2M | Q4 2025 | Q3 2026 | yes | |
| LIFE SCIENCES PENNSYLVANIA | 5 | $6,000 | Q4 2025 | Q3 2026 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | 5 | $1.6M | Q4 2025 | Q3 2026 | yes | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | THE MCMANUS GROUP | 5 | $0 | Q4 2025 | Q3 2026 | yes |
| MEDTRONIC INC | 5 | $6.8M | Q4 2025 | Q3 2026 | yes | |
| NOVOCURE INC. | 5 | $720K | Q4 2025 | Q3 2026 | yes | |
| PHILIPS HOLDING USA INC. | 5 | $2.9M | Q4 2025 | Q3 2026 | yes | |
| ROCHE DIAGNOSTICS | THE MCMANUS GROUP | 5 | $200K | Q4 2025 | Q3 2026 | yes |
| THE COOK GROUP INC. | 5 | $680K | Q4 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES, INC. | ML STRATEGIES, LLC | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATION | THORN RUN PARTNERS | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| NOVOCURE INC. | WILLIAMS AND JENSEN, PLLC | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| ZIMMER BIOMET | THE MCMANUS GROUP | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| ALZHEIMER'S ASSOCIATION | 3 | $3.7M | Q1 2026 | Q3 2026 | yes | |
| CURE SMA | 3 | $225K | Q1 2026 | Q3 2026 | yes | |
| INSIGHTEC, INC. | RS GROUP CONSULTING LLC | 3 | $90K | Q1 2026 | Q3 2026 | yes |
| NATIONAL HEALTH COUNCIL | 3 | $63K | Q4 2025 | Q3 2026 | yes | |
| SIEMENS MEDICAL SOLUTIONS USA, INC | 3 | $2.3M | Q4 2025 | Q2 2026 | yes |